The best investors are not afraid to go against the grain. And an investment in Viatris, which has an average analyst rating of only hold, would certainly fit the bill. Might patient investors be able to find value in this stock? Let's dive into numbers and see for ourselves.
Let's start our value analysis with the price to book (P/B) ratio. This is perhaps the most basic measure of a company's valuation, which is its market value divided by its book value. Book value refers to the sum of all of the company's tangible assets minus its liabilities -- you can also think of it as the company's equity value.
Traditionally, value investors would look for companies with a ratio of less than 1 (meaning that the market value was smaller than the company's book value), but such opportunities are very rare these days. So we tend to look for company's whose valuations are less than their sector and market average. The P/B ratio for Viatris is 0.6, compared to its sector average of 4.16 and the S&P500's average P/B of 2.95.
The most common metric for valuing a company is its Price to Earnings (P/E) ratio. It's simply today's stock price of 9.65 divided by either its trailing or forward earnings, which for Viatris are $1.71 and $2.9 respectively. Based on these values, the company's trailing P/E ratio is 5.6 and its forward P/E ratio is 3.3. By way of comparison, the average P/E ratio of the Health Care sector is 24.45 and the average P/E ratio of the S&P 500 is 15.97.
The problem with P/E ratios is that they don't take into account the growth of earnings. This means that a company with a higher than average P/E ratio may still be undervalued if it has extremely high projected earnings growth. Conversely, a company with a low P/E ratio may not present a good value if its projected earnings are stagnant.
When we divide Viatris's P/E ratio by its projected 5 year earnings growth rate, we obtain its Price to Earnings Growth (PEG) ratio of -0.76. A PEG ratio of 1 or less may indicate the company is undervalued in terms of its growth potential. On the other hand, a PEG ratio higher than 1 could indicate that investors are paying too high a premium for these growth levels. Bear in mind, however, that the 5 year earnings growth estimate could very well be an over or underestimate!
Indebted or mismanaged companies can't sustain shareholder value for long, even if they have strong earnings. For this reason, considering Viatris's ability to meet its debt obligations is an important aspect of its valuation. By adding up its current assets, then subtracting its inventory and prepaid expenses, and then dividing the whole by its current liabilities, we obtain the company's Quick Ratio of 0.764. Since VTRS's is lower than 1, it does not have the liquidity necessary to meet its current liabilities.
One last metric to check out is Viatris's free cash flow of $2,5 Billion This represents the total sum of all the company's inflows and outflows of capital, including the costs of servicing its debt. It's the final bottom line of the company, which it can use to re-invest or to pay its investors a dividend. With such healthy cash flows, investors can expect Viatris to keep paying its 5.0% dividend.
Are analysts missing the big picture on Viatris? Or did they unearth some damning information to consider about the company that trumps the stock's strong valuation and growth potential?